163 related articles for article (PubMed ID: 32946005)
1. Solid state NMR assignments of a human λ-III immunoglobulin light chain amyloid fibril.
Pradhan T; Annamalai K; Sarkar R; Hegenbart U; Schönland S; Fändrich M; Reif B
Biomol NMR Assign; 2021 Apr; 15(1):9-16. PubMed ID: 32946005
[TBL] [Abstract][Full Text] [Related]
2. Seeded fibrils of the germline variant of human λ-III immunoglobulin light chain FOR005 have a similar core as patient fibrils with reduced stability.
Pradhan T; Annamalai K; Sarkar R; Huhn S; Hegenbart U; Schönland S; Fändrich M; Reif B
J Biol Chem; 2020 Dec; 295(52):18474-18484. PubMed ID: 33093170
[TBL] [Abstract][Full Text] [Related]
3. Mechanistic insights into the aggregation pathway of the patient-derived immunoglobulin light chain variable domain protein FOR005.
Pradhan T; Sarkar R; Meighen-Berger KM; Feige MJ; Zacharias M; Reif B
Nat Commun; 2023 Jun; 14(1):3755. PubMed ID: 37353525
[TBL] [Abstract][Full Text] [Related]
4. Solid-state NMR chemical shift assignments for AL-09 V
Piehl DW; Blancas-Mejía LM; Ramirez-Alvarado M; Rienstra CM
Biomol NMR Assign; 2017 Apr; 11(1):45-50. PubMed ID: 27771830
[TBL] [Abstract][Full Text] [Related]
5. Fatal amyloid formation in a patient's antibody light chain is caused by a single point mutation.
Kazman P; Vielberg MT; Pulido Cendales MD; Hunziger L; Weber B; Hegenbart U; Zacharias M; Köhler R; Schönland S; Groll M; Buchner J
Elife; 2020 Mar; 9():. PubMed ID: 32151314
[TBL] [Abstract][Full Text] [Related]
6. Identification of two principal amyloid-driving segments in variable domains of Ig light chains in systemic light-chain amyloidosis.
Brumshtein B; Esswein SR; Sawaya MR; Rosenberg G; Ly AT; Landau M; Eisenberg DS
J Biol Chem; 2018 Dec; 293(51):19659-19671. PubMed ID: 30355736
[TBL] [Abstract][Full Text] [Related]
7. Molecular mechanism of amyloidogenic mutations in hypervariable regions of antibody light chains.
Rottenaicher GJ; Weber B; Rührnößl F; Kazman P; Absmeier RM; Hitzenberger M; Zacharias M; Buchner J
J Biol Chem; 2021; 296():100334. PubMed ID: 33508322
[TBL] [Abstract][Full Text] [Related]
8. Cryo-EM structure of cardiac amyloid fibrils from an immunoglobulin light chain AL amyloidosis patient.
Swuec P; Lavatelli F; Tasaki M; Paissoni C; Rognoni P; Maritan M; Brambilla F; Milani P; Mauri P; Camilloni C; Palladini G; Merlini G; Ricagno S; Bolognesi M
Nat Commun; 2019 Mar; 10(1):1269. PubMed ID: 30894521
[TBL] [Abstract][Full Text] [Related]
9. Cryo-EM reveals structural breaks in a patient-derived amyloid fibril from systemic AL amyloidosis.
Radamaker L; Baur J; Huhn S; Haupt C; Hegenbart U; Schönland S; Bansal A; Schmidt M; Fändrich M
Nat Commun; 2021 Feb; 12(1):875. PubMed ID: 33558536
[TBL] [Abstract][Full Text] [Related]
10. A Substantial Structural Conversion of the Native Monomer Leads to in-Register Parallel Amyloid Fibril Formation in Light-Chain Amyloidosis.
Lecoq L; Wiegand T; Rodriguez-Alvarez FJ; Cadalbert R; Herrera GA; Del Pozo-Yauner L; Meier BH; Böckmann A
Chembiochem; 2019 Apr; 20(8):1027-1031. PubMed ID: 30565364
[TBL] [Abstract][Full Text] [Related]
11. Cryo-EM structure of a light chain-derived amyloid fibril from a patient with systemic AL amyloidosis.
Radamaker L; Lin YH; Annamalai K; Huhn S; Hegenbart U; Schönland SO; Fritz G; Schmidt M; Fändrich M
Nat Commun; 2019 Mar; 10(1):1103. PubMed ID: 30894526
[TBL] [Abstract][Full Text] [Related]
12. Partially folded intermediates as critical precursors of light chain amyloid fibrils and amorphous aggregates.
Khurana R; Gillespie JR; Talapatra A; Minert LJ; Ionescu-Zanetti C; Millett I; Fink AL
Biochemistry; 2001 Mar; 40(12):3525-35. PubMed ID: 11297418
[TBL] [Abstract][Full Text] [Related]
13. Kinetic control in protein folding for light chain amyloidosis and the differential effects of somatic mutations.
Blancas-Mejía LM; Tischer A; Thompson JR; Tai J; Wang L; Auton M; Ramirez-Alvarado M
J Mol Biol; 2014 Jan; 426(2):347-61. PubMed ID: 24157440
[TBL] [Abstract][Full Text] [Related]
14. Coexistence of protein AA and immunoglobulin light-chain fragments in amyloid fibrils.
Westermark P; Natvig JB; Anders RF; Sletten K; Husby G
Scand J Immunol; 1976; 5(1-2):31-6. PubMed ID: 57640
[TBL] [Abstract][Full Text] [Related]
15. Differential effects on light chain amyloid formation depend on mutations and type of glycosaminoglycans.
Blancas-Mejía LM; Hammernik J; Marin-Argany M; Ramirez-Alvarado M
J Biol Chem; 2015 Feb; 290(8):4953-4965. PubMed ID: 25538238
[TBL] [Abstract][Full Text] [Related]
16. Mutations in specific structural regions of immunoglobulin light chains are associated with free light chain levels in patients with AL amyloidosis.
Poshusta TL; Sikkink LA; Leung N; Clark RJ; Dispenzieri A; Ramirez-Alvarado M
PLoS One; 2009; 4(4):e5169. PubMed ID: 19365555
[TBL] [Abstract][Full Text] [Related]
17. Mass spectrometry characterization of light chain fragmentation sites in cardiac AL amyloidosis: insights into the timing of proteolysis.
Lavatelli F; Mazzini G; Ricagno S; Iavarone F; Rognoni P; Milani P; Nuvolone M; Swuec P; Caminito S; Tasaki M; Chaves-Sanjuan A; Urbani A; Merlini G; Palladini G
J Biol Chem; 2020 Dec; 295(49):16572-16584. PubMed ID: 32952127
[TBL] [Abstract][Full Text] [Related]
18. (1)H, (15)N and (13)C resonance assignments for 3rC and 3rCWP: amyloidogenic variants of imunoglobulin λ 3 light-chain.
Gil-Rodríguez P; Amero C
Biomol NMR Assign; 2015 Apr; 9(1):139-42. PubMed ID: 24816896
[TBL] [Abstract][Full Text] [Related]
19. Light chain mutations contribute to defining the fibril morphology in systemic AL amyloidosis.
Karimi-Farsijani S; Pfeiffer PB; Banerjee S; Baur J; Kuhn L; Kupfer N; Hegenbart U; Schönland SO; Wiese S; Haupt C; Schmidt M; Fändrich M
Nat Commun; 2024 Jun; 15(1):5121. PubMed ID: 38879609
[TBL] [Abstract][Full Text] [Related]
20. A constant domain mutation in a patient-derived antibody light chain reveals principles of AL amyloidosis.
Rottenaicher GJ; Absmeier RM; Meier L; Zacharias M; Buchner J
Commun Biol; 2023 Feb; 6(1):209. PubMed ID: 36823438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]